Armodafinil: a new treatment for excessive sleepiness.

Article Details

Citation
Copy to clipboard

Lankford DA

Armodafinil: a new treatment for excessive sleepiness.

Expert Opin Investig Drugs. 2008 Apr;17(4):565-73. doi: 10.1517/13543784.17.4.565 .

PubMed ID
18363520 [ View in PubMed
]
Abstract

BACKGROUND: Armodafinil is a wake-promoting agent developed by Cephalon that was approved in mid-2007 for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea and shift work disorder. It is the R-enantiomer of the compound modafinil. Like modafinil, the mechanism of action for armodafinil is not fully characterized. OBJECTIVE: To determine what data are available to support the potential use of armodafinil in clinical settings. METHODS: There are limited data on armodafinil available in the public domain, particularly in regard to chemistry and pharmacokinetics/dynamics. Data were reviewed from refereed journals, scientific presentations, and published labeling. RESULTS/CONCLUSION: Clinical trials demonstrated efficacy and safety profiles that were similar to those of the parent compound with wake promotion sustained throughout the day. The longer duration of effect has the potential for improved patient response and compliance but this will require further study. The primary commercial challenge may be the future availability of generic modafinil.

DrugBank Data that Cites this Article

Drugs